249 related articles for article (PubMed ID: 18590011)
1. [National economic consequences of vaccines].
Bergman A; Persson U
Lakartidningen; 2008 May 28-Jun 3; 105(22):1680-4. PubMed ID: 18590011
[No Abstract] [Full Text] [Related]
2. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
3. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
[TBL] [Abstract][Full Text] [Related]
4. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia.
Moore D; Bigham M; Patrick D
Can Commun Dis Rep; 2003 Jun; 29(11):97-104. PubMed ID: 12794969
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada.
Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J
Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137
[TBL] [Abstract][Full Text] [Related]
7. [Vaccination--value for money?].
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
[TBL] [Abstract][Full Text] [Related]
8. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
9. The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.
Alexander PG; Chartrand SA; Davies TJ; Gaines BM; Oster G; Shurin P; Tamsky L; Thornton DK; Wittert W
Manag Care Interface; 2001; Suppl C():10-28; quiz 29-30. PubMed ID: 11724029
[No Abstract] [Full Text] [Related]
10. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
Ortqvist A; Jönsson B; Baltussen R; Ament A
Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of pneumococcal conjugate vaccination in Finland.
Salo H; Sintonen H; Nuorti JP; Linna M; Nohynek H; Verho J; Kilpi T
Scand J Infect Dis; 2005; 37(11-12):821-32. PubMed ID: 16308215
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the United States during an influenza pandemic.
Dhankhar P; Grabenstein JD; O'Brien MA; Dasbach EJ
Clin Ther; 2010 Aug; 32(8):1501-16. PubMed ID: 20728763
[TBL] [Abstract][Full Text] [Related]
13. Challenges in cost-effectiveness analyses of hospital interventions to improve quality.
Davis MM
Infect Control Hosp Epidemiol; 2008 May; 29(5):395-7. PubMed ID: 18419359
[No Abstract] [Full Text] [Related]
14. Cost-utility analysis of patient care in children with meningeal signs.
Oostenbrink R; Oostenbrink JB; Moons KG; Derksen-Lubsen G; Essink-Bot ML; Grobbee DE; Redekop WK; Moll HA
Int J Technol Assess Health Care; 2002; 18(3):485-96. PubMed ID: 12391942
[TBL] [Abstract][Full Text] [Related]
15. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
Silfverdal SA; Berg S; Hemlin C; Jokinen I
Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps.
Vold Pepper P; Owens DK
Clin Infect Dis; 2000 Jan; 30(1):157-64. PubMed ID: 10619745
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
Lucioni C; Mazzi S
Vaccine; 2006 Mar; 24(11):1735. PubMed ID: 16356601
[No Abstract] [Full Text] [Related]
18. [New vaccines to be considered in pediatrics and school health services].
Trollfors B
Lakartidningen; 2008 May 28-Jun 3; 105(22):1660-4. PubMed ID: 18590007
[No Abstract] [Full Text] [Related]
19. [Pneumococcal vaccine for the elderly--ineffective but cost-efficient?].
Håkansson J
Lakartidningen; 2000 Dec; 97(50):5958. PubMed ID: 11188544
[No Abstract] [Full Text] [Related]
20. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.
Claes C; Reinert RR; von der Schulenburg JM
Eur J Health Econ; 2009 Feb; 10(1):25-38. PubMed ID: 18379830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
